leadf
logo-loader
viewMGC Pharmaceuticals Ltd
(
LSE:MXCOTC:MGCLFFRA:H5OASX:MXC
)

MGC Pharmaceuticals bags $10M for medical cannabis growth

MGC’s cosmetics and dermatological product sales is growing.

rsz_shutterstock_283785782.jpg
MGC is also assessing acquisition opportunities

MGC Pharmaceuticals (ASX:MXC) has closed an oversubscribed share placement after receiving commitments to raise $10 million via the issue of shares at $0.065 each.

MGC will use the funds to fast-track its growth objectives, including the research and development of pharmaceutical-grade cannabis based products.

In addition, the funds will be used to expand sales of the company’s cosmetics and dermatological product ranges.

MGC is also aggressively assessing acquisition opportunities in the Australian and international medicinal cannabis sector.

In January, MGC received approval in Europe for its cannabidiol based dermatological products for the relief of acne, psoriasis and seborrhoea skin conditions.

The development of a dermatologically tested cannabidiol skin care range is a key priority for MGC, given the significant commercial opportunity that such products represent globally.

In 2016, the company signed a distribution deal in California, U.S. for over 60,000 units of cannabidiol-based anti-aging cosmetics products with a contract value of about €1.2 million.

Carrying through a capital raise of $10 million is a substantial validation of the enormous potential of medical cannabis globally and MGC’s potential in this rapidly growing industry.

The company’s share price has increased by more than 80% since the start of 2017, last trading at $0.079.

Quick facts: MGC Pharmaceuticals Ltd

Follow
LSE:MXC

Price: 3.2492 GBX

Market Cap: £78.09 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

MGC Pharmaceuticals: Continuous global breakthroughs as progress accelerates

Proactive Research Analyst Ed Stacey presents his analysis on MGC Pharmaceuticals (LON:MXC).  The company recently announced that it has received a UK import permit for CannEpil+, which is MGC’s cannabis-derived therapy for refractory epilepsy, to be used initially on a compassionate access...

1 week, 5 days ago

2 min read